CRL Charles River Laboratories International Inc.

Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test

Building upon its flagship Endosafe® cartridge technology, Charles River Laboratories International, Inc. (NYSE: CRL) has advanced this innovation one step further and combined it with their recombinant cascade reagent (rCR) to launch the Endosafe® Trillium™ rCR cartridge offering. Expanding its robust bacterial endotoxin testing (BET) portfolio with a new animal-free testing solution, this offering, which builds on Charles River’s existing Trillium rCR vial product, enhances testing efficiency and accelerates manufacturing timelines while simultaneously contributing to Charles River's (Replacement, Reduction, Refinement, and Responsibility) and further progressing our clients goals on sustainability and animal welfare.

Designed to deliver rapid, quantitative results, the rCR cartridges are pre-loaded with all the reagents required to perform an endotoxin test, eliminating need for preparation of multiple reagents, and reducing the opportunity for technician error. Additionally, the product is fully aligned and integrated with Charles River’s existing suite of Endosafe cartridge instrumentation and software, allowing for current limulus amebocyte lysate (LAL) cartridge clients to transition seamlessly.

Historically, endotoxin testing has relied on the Atlantic horseshoe crab, whose blood contains LAL, an aqueous extract of blood cells. LAL is the critical component of the testing of implantable medical devices and injectable pharmaceutical products to ensure the absence of endotoxins that can cause pyrogenic responses and symptoms of septic shock. The Trillium rCR formulation within the cartridge technology detects and quantifies natural environmental endotoxins by simulating the LAL enzymatic cascade through an optimized formulation and composition of three recombinant proteins (recombinant Factor C, recombinant Factor B, and recombinant proclotting enzyme) and a specific concentration of key components. Our extensive data package supporting our proprietary matrix demonstrates assay superiority in accuracy, comparability, and robustness.

Charles River continues to apply the highest scientific standards when offering new and innovative products in its BET portfolio. The Trillium cartridge was developed following a data-driven decision-making process to create a product that ultimately will provide the highest quality results among recombinant technologies and ensure patient safety. Samples representing a wide group of product types from global geographies were tested through a beta study of existing cartridge clients. The results for these samples showed equivalency within that data set, supporting the claim of equivalency to LAL.

Approved Quotes

  • “The launch of Charles River’s Endosafe® Trillium™ cartridge revolutionizes the way the industry approaches endotoxin testing while strengthening our united commitment to sustainability initiatives. This year, as we celebrate the 20th anniversary of the original Endosafe LAL reagent cartridge technology, we are excited to bring a new animal-free option to clients that leverages innovative technology, while continuing to offer our LAL-based offerings for clients whose work requires them.” – Birgit Girshick, Corporate Executive Vice President & Chief Operating Officer, Charles River.
  • “We are proud to support our clients’ wide range of BET needs with this first-ever animal-free cartridge. In conjunction with our LAL-based cartridges, which utilize 95% less horseshoe crab raw material required for a traditional bacterial endotoxin test, the Trillium cartridge builds on our portfolio to provide our clients with robust animal-free and animal-reduced offerings.” – Gregory Marshall, Vice President and General Manager, Microbial Solutions, Charles River.
  • “Using the Endosafe® Trillium™ rCR cartridges alongside our routine testing was straightforward for our technicians, as the test method remains identical, and the results are reported the same way. We were pleased with the technology implementation, quality of data, and onboarding as it was simple and seamless, which is ideal when introducing such an impactful change in the microbiology lab. We look forward to moving to Endosafe® Trillium™ rCR cartridges for routine testing later in the year as part of our environmental sustainability efforts.” – Greg White, Microbiology Laboratory Supervisor & Blackpool STEM Lead, DePuy Synthes International.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit .

EN
29/01/2024

Underlying

Reports on Charles River Laboratories International Inc.

Charles River Laboratories Int'l, Inc.: Update to credit analysis

Charles River's credit profile reflects its strong and consistent free cash flow, offset by its sensitivity to R&D budgets of clients and research funding availability.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 December 2025 in which we reassessed the appropriateness of the r...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch